Even though prostate cancer is the second leading cause of cancer death in men in the United States, some patients may wonder whether treatment is worse than the disease. The... | [more]
Welcome to Dana-Farber/Harvard Cancer Center
Dana-Farber/Harvard Cancer Center (DF/HCC) is the largest comprehensive cancer center in the world, bringing together the cancer research efforts of our seven member institutions: Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Children’s Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, and Massachusetts General Hospital.Funded by a grant from the National Cancer Institute, we have joined these seven renowned Harvard-affiliated medical centers into one collective force dedicated to the fight against cancer. Based in Boston, DF/HCC consists of more than 1,000 researchers with a singular goal — to find new and innovative ways to combat cancer.
Announcements
- A Celebration of the Career of George P. Canellos - Symposium 10/17 Posted: 10-09-08
- JGIM CALL FOR SUBMISSIONS - CANCER SURVIVORSHIP SUPPLEMENT Posted: 10-07-08
- Request for Applications: DF/HCC SPORE in Breast Cancer Developmental Project Award Posted: 09-29-08
Latest Cancer News
Thinking therapeutically: Scientists in search of smarter tests and treatments for prostate cancer
Beyond survival: Bettering men’s quality of life following prostate cancer treatment
Few clinicians understand the consequences of prostate cancer treatment better than urological surgeon-scientist Martin Sanda, MD, director of the multidisciplinary prostate... | [more]
Unique randomized trial tests VEGF inhibitor in patients with recurrent glioblastoma
Glioblastoma, the most common and lethal type of malignant brain tumor, has a poor prognosis and very few chemotherapeutic options. Despite surgery, radiotherapy, and... | [more]
Health Communication Core
The Health Communication Core provides communication support in areas such as cancer prevention education and communication, recruitment to clinical research studies,... | [more]
